Efficacy and tolerance of Urea compared with Vaptans for long-term treatment of patients with SIADH

Clinical Journal of the American Society of Nephrology

Volumn 7, Issue 5, 2012, Pages 742-747

  Soupart, Alain ^a,b   Coffernils, Michel ^a   Couturier, Bruno ^b   Gankam Kengne, Fabrice ^b   Decaux, Guy ^b  

^a Department of Internal Medicine   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

SATAVAPTAN; SODIUM; TOLVAPTAN; UREA; VASOPRESSIN V2 RECEPTOR;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; HYPERNATREMIA; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LONG TERM CARE; MALE; PROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BENZAZEPINES; FEMALE; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MALE; MIDDLE AGED; MORPHOLINES; RECEPTORS, VASOPRESSIN; SODIUM; SPIRO COMPOUNDS; TIME FACTORS; UREA;

EID: 84860786148     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06990711     Document Type: Article

References (48)

1. Adrogué HJ, Madias NE: Hyponatremia. N Engl J Med 342: 1581-1589, 2000
2. Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati H, Decaux G: Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J AmSoc Nephrol 1: 1154-1160, 2006
3. Anpalahan M: Chronic idiopathic hyponatremia in older people due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) possibly related to aging. J AmGeriatr Soc 49: 788-792, 2001
4. Smith D, Moore K, Tormey W, Baylis PH, Thompson CJ: Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 287: E1019-E1023, 2004
5. Zietse R, van der Lubbe N, Hoorn E: Current and future treatment options in SIADH. Nephrol Dial Transplant Plus 2[Suppl 3]: iii12-iii19, 2009
6. Decaux G, Waterlot Y, Genette F, Mockel J: Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med 304: 329-330, 1981
7. Decaux G: Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron 35: 82-88, 1983
8. Decaux G, Brimioulle S, Genette F, Mockel J: Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 69: 99-106, 1980
9. Decaux G, Genette F: Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed) 283: 1081-1083, 1981
10. Decaux G, Unger J, Brimioulle S, Mockel J: Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. JAMA 247: 471-474, 1982
11. Decaux G: Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110: 582-584, 2001
12. Soupart A, Decaux G: Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol 46: 149-169, 1996
13. Decaux G, Andres C, Gankam Kengne F, Soupart A: Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 14: R184, 2010
14. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 371: 1624-1632, 2008
15. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 91: 2145-2152, 2006
16. Velez J, Dopson S, Sanders D, Delay T, Arthur J: Intravenous Conivaptan for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: A single-center experience. Nephrol Dial Transplant 25: 1524-1531, 2010
17. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006
18. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS; SALTWATER Investigators: Oral tolvaptan is safe and effective in chronic hyponatremia. J AmSoc Nephrol 21: 705-712, 2010
19. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS; SALT Investigators: Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 164: 725-732, 2011
20. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C; Tolvaptan Investigators: Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 97: 1064-1067, 2006
21. Cluitmans FH, Meinders AE:Management of severe hyponatremia: Rapid or slow correction? Am J Med 88: 161-166, 1990
22. Soupart A, Silver S, Schroeder B, Sterns R, Decaux G: Comparison of mortality and brain composition in hyponatremic rats treated with vasopressin V1-V2 or V2-receptor antagonists or water diuresis. J Am Soc Nephrol 14: 747A, 2003
23. Weinberg M, Donohoe J: Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone: Rapid correction with osmotic agents. South Med J 78: 348-351, 1985
24. Berl T: Mannitol: A therapeutic alternative in the treatment of acute hyponatremia? Crit Care Med 28: 2152-2153, 2000
25. Verbalis JG, Baldwin EF, Neish PN, Robinson AG: Effect of protein intake and urea on sodium excretion during inappropriate antidiuresis in rats. Metabolism 37: 46-54, 1988
26. Berl T: Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 19: 1076-1078, 2008
27. Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE: Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr 148: 128-131, 2006
28. Chehade H, Rosato L, Girardin E, Cachat F: Inappropriate antidiuretic hormone secretion: long-termsuccessful urea treatment. Acta Paediatr 101: e39-e42, 2011
29. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C: Nephrogenic syndrome of inappropriate antidiuresis in adults: High phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 18: 606-612, 2007
30. Verhoeven A, Musch W, Decaux G: Treatment of the polydipsiahyponatremia syndrome with urea. J Clin Psychiatry 66: 1372-1375, 2005
31. Kawai N, Ishikawa K, Nemoto K, Katano T, Takahashi S, Hori T, Asada T: Oral urea treatment for polydipsia-hyponatremia syndrome in patients with schizophrenia. J Clin Psychopharmacol 29: 499-501, 2009
32. Stahle J: Medical treatment of fluctuant hearing loss in Meniere's disease. Am J Otol 5: 529-533, 1984
33. Javid M: Urea; new use of an old agent; reduction of intracranial and intraocular pressure. Surg Clin North Am 38: 907-928, 1958
34. Soupart A, Stenuit A, Perier O, Decaux G: Limits of brain tolerance to daily increments in serum sodium in chronically hyponatraemic rats treated with hypertonic saline or urea: Advantages of urea. Clin Sci (Lond) 80: 77-84, 1991
35. Soupart A, Penninckx R, Stenuit A, Decaux G: Azotemia (48 h) decreases the risk of brain damage in rats after correction of chronic hyponatremia. Brain Res 852: 167-172, 2000
36. Soupart A, Silver S, Schroöeder B, Sterns R, Decaux G: Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-inositol) in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol 13: 1433-1441, 2002
37. Soupart A, Schroeder B, Decaux G: Treatment of hyponatremia by urea decreases risks of brain complications in rats. Brain osmolytes contents analysis. Nephrol Dial Transplant 22: 1856-1863, 2007
38. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 119 (7 suppl 1): S79-82, 2006
39. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G: Mild chronic hyponatremia is associatedwith falls, unsteadiness, and attention deficits. Am J Med 119: 71, e1-e8, 2006
40. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G: Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 101: 583-588, 2008
41. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA: Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 5: 275-280, 2010
42. Sandhu HS, Gilles E, DeVita MV, Panagopoulos G, Michelis MF: Hyponatremia associated with large-bone fracture in elderly patients. Int Urol Nephrol 41: 733-737, 2009
43. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, Carter EA, Resnick HE: Hyponatremia-induced osteoporosis. J Bone Miner Res 25: 554-563, 2010
44. Barsony J, Manigrasso M, Xu Q, Tam H, Verbalis J. Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats [published online ahead of print January 5, 2012]. Age (Dordr) doi:10.1007/s11357-011-9347-9
45. Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD:Mortality and serum sodium: do patients die from or with hyponatremia? Clin J Am Soc Nephrol 6: 960-965, 2011
46. Konstam M, Gheorghiade M, Burnett J Jr, Grinfield L, Maggioni A, Swedberg K, Udelson J, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Effects of oral Tovalptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA 297: 1319-1331, 2007
47. Gross P, Wagner A, Decaux G: Vaptans are not the mainstay of treatment in hyponatremia: Perhaps not yet. Kidney Int 80: 594-600, 2011
48. Decaux G, Musch W, Soupart A: Management of hypotonic hyponatremia. Acta Clin Belg 65: 437-445, 2010